Targeting a specific variant of the androgen receptor in advanced prostate cancer
Targeting AR variants in advanced prostate cancer
This study is looking at new ways to help men with advanced prostate cancer that doesn't respond to common treatments by targeting a specific part of the cancer called AR-V7, with the hope of making existing therapies work better.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California at Davis NIH-funded |
| Lab location | 1 site (Davis, United States) |
| Project ID | NIH-10538636 on NIH RePORTER |
What this research studies
This research focuses on advanced prostate cancer that has become resistant to standard treatments like enzalutamide and abiraterone. It investigates the role of a specific variant of the androgen receptor, known as AR-V7, which contributes to this resistance. The researchers are developing new small molecule inhibitors that specifically target AR-V7 to improve treatment outcomes. By synthesizing and testing these novel compounds, they aim to enhance the effectiveness of existing therapies for patients with castration-resistant prostate cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are men diagnosed with castration-resistant prostate cancer who have not responded to standard anti-androgen therapies.
Not a fit: Patients with early-stage prostate cancer or those who have not yet undergone treatment with enzalutamide or abiraterone may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new treatment option for patients with advanced prostate cancer who have developed resistance to current therapies.
How similar studies have performed: While targeting AR-V7 is a novel approach, previous studies have shown promise in targeting androgen receptor variants in cancer treatment, indicating potential for success.
Where this research is happening
Davis, United States
- University of California at Davis — Davis, United States (Active)
Researchers
- Principal investigator: Gao, Allen C. — University of California at Davis
- Study coordinator: Gao, Allen C.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.